The selected target: $100 per share, a round-number psychological milestone roughly 56% above recent trading levels. Strongest bullish factor: Accelerating adoption of the Atera platform, a 74% gross margin, and raised 2026 revenue guidance of $610–$630 million.

Caris Life Sciences shares recently traded near $24.58, making a move to a $30 stock price target roughly a 22% gain. The $30 level sits squarely within Wall Street's published range, with JPMorgan carrying a $30 target and BTIG a $33 target.

The selected price target is $200 , a round-number level that sits roughly 50% above Moderna's recent trading price near $133. The strongest bullish catalyst is the first-ever positive Phase 3 result for a personalized mRNA cancer vaccine (intismeran, developed with Merck), which validated the platform beyond COVID-19.

Paycom Software shares last traded near $227, leaving roughly 10% of upside to the widely discussed $250 price level. The strongest bullish case rests on a second-quarter 2026 earnings beat, raised full-year guidance, and an aggressive $2 billion buyback authorization.

Newmont Corporation ( NEM ) trades near $128, and the $150 level represents a roughly 17% advance that also appears in several Wall Street price targets. The strongest bullish case rests on a durable high gold price, improving operational momentum, and Newmont's position as the world's largest gold miner by market value.

CAI shares closed at $24.58, up about 59.8% from $15.38 roughly 30 calendar days earlier, marking a sharp re-rating after a prolonged drawdown. The rally was driven by record second-quarter 2026 results reported on August 5, including revenue of $263.7 million, up 45% year over year, and a full-year guidance increase.

Newmont (NEM) rose roughly 38% over the trailing 30 days, from about $92.49 to $127.64, driven mainly by a sharp rebound in gold prices. The rally accelerated in August as safe-haven demand and lower long-term Treasury yields pushed bullion back above $4,400 per ounce.

Moderna shares climbed roughly 123% over the past 30 days, rising from about $59.66 in late July to a closing price near $133.32. The surge was driven primarily by positive Phase 3 data for intismeran autogene, Moderna's personalized mRNA cancer vaccine developed with Merck (MRK) .

Paycom Software (PAYC) shares climbed roughly 57% over the last 30 days, rising from about $144 on July 21 to a closing price of $226.72 on August 20. The rally was driven primarily by stronger-than-expected second-quarter 2026 results released on August 5, when the company beat on revenue and earnings and raised its full-year guidance.

10x Genomics (TXG) shares climbed roughly 35.7% over the trailing 30 days, rising from a closing price of $47.05 to about $63.87. The advance was powered by a stronger-than-expected Q2 2026 report, an upward revision to full-year revenue guidance, and early enthusiasm for the new Atera spatial biology platform.

The target: Tesla, Inc. ( TSLA ) trades near $350, making $500 a roughly 40% move and a widely discussed psychological milestone. Bullish case: Robotaxi expansion, the Optimus humanoid robot, energy storage growth, and Full Self-Driving (FSD) progress anchor the long-term thesis.

TLSA gained +7.48% to $1.15 during regular trading Thursday, rebounding from Wednesday's -4.46% close at $1.07. The move occurred in market hours on heavy volume of roughly 2.09M shares versus a ~509k average.

The central question is whether JEDI can climb back toward the $40 psychological level, roughly one-third above its recent price near $30. The ETF has already traded as high as $42.99 over the past 52 weeks, showing the $40 zone is within its demonstrated range rather than uncharted territory.

Selected target: $2 per share, a round-number recovery level representing roughly 85–90% upside from the recent price near $1.07. Strongest bullish factor: A differentiated clinical pipeline led by Foralumab, an intranasal anti-CD3 antibody with FDA Fast Track designation for non-active secondary progressive multiple sclerosis (na-SPMS).

AVGO has faced recent sentiment pressure from competitive developments in custom silicon, contributing to short-term price weakness amid broader semiconductor volatility. MU has delivered exceptional year-to-date gains driven by sustained demand for high-bandwidth memory in artificial intelligence applications.

Alector (ALEC) shares climbed roughly 70% over the past 30 days, rising from about $1.43 to $2.43, driven by a better-than-expected quarterly report and renewed momentum in its neurodegeneration pipeline. The stock's second-quarter results exceeded consensus estimates, with a narrower loss per share and revenue that surpassed analyst forecasts.

WMT fell -7.88% to $105.29 intraday Thursday, extending a roughly -6% premarket drop after Q2 results, versus Wednesday's $114.30 close. Primary catalyst: U.S. comparable sales rose just +2.6% (ex-fuel), missing the ~3.8% consensus and marking the slowest growth in six years, driven by Medicare drug-price caps pressuring pharmacy sales.

SCSC rallied +26.97% to $65.29 during the regular trading session, up from the prior close of $51.42. The move was driven by a strong Q4 FY2026 earnings report: net sales of $953.1 million, up +17.3% year over year, and GAAP diluted EPS of $1.24 versus $0.88 a year earlier.

AAP is down -20.43% to roughly $44.70, extending a premarket slide of about -15% into the regular session following its Q2 FY2026 earnings report. Adjusted EPS of $1.03 beat the $0.81 consensus, but revenue of $2.0 billion missed the $2.04 billion estimate and was flat year-over-year.

MRNA is down -16.71% to $145.24 in regular trading, after closing Wednesday at $174.38. The pullback follows Wednesday's historic +176.97% surge on positive Phase 3 melanoma data for intismeran, its personalized mRNA cancer vaccine developed with Merck.